Raf-1: a novel cardiac troponin T kinase
- First Online:
- Cite this article as:
- Pfleiderer, P., Sumandea, M.P., Rybin, V.O. et al. J Muscle Res Cell Motil (2009) 30: 67. doi:10.1007/s10974-009-9176-y
- 75 Views
Phosphorylation of cardiac troponin is a key mechanism involved in regulation of contractile function. In vitro kinase assays revealed that lysates prepared from resting cardiomyocytes contain cardiac troponin I (cTnI) and cTnT kinase activity. cTnI phosphorylation is inhibited by pharmacologic inhibitors of PKA, PKC, Rho kinase and PKC effectors such as RSK and PKD; these kinase inhibitors do not inhibit phosphorylation of cTnT. Rather, cTnT phosphorylation is decreased by the Raf inhibitor GW5074. In vitro kinase assays show that recombinant Raf phosphorylates cTnT, and that Raf-dependent cTnT phosphorylation is abrogated by a T206E substitution; Raf does not phosphorylate cTnI. These studies identify Raf-dependent cTnT-Thr206 phosphorylation as a novel mechanism that would link growth factor-dependent signaling pathways to dynamic changes in cardiac contractile function.
KeywordsCardiac troponin TRaf-1GW5074CardiomyocytesPhosphorylation
Protein kinase A
Protein kinase C
Protein kinase D
Phosphoinositide-dependent protein kinase
Apoptosis signal-regulating kinase-1
Ribosomal S6 kinase
Myofilament contraction and relaxation is regulated, in a Ca2+-dependent manner, by the cooperative interaction of cardiac troponin (cTn) with tropomyosin (Tm). The troponin complex is comprised of three distinct proteins with specific functions. Troponin C (TnC) binds Ca2+, troponin I (TnI) inhibits the myosin–actin cross-bridge formation, and troponin T (TnT) binds Tm and tethers the cTn complex to the thin filament. TnT functions as a lever to transmit signals generated by Ca2+-dependent conformational changes in TnC-TnI to Tm, regulating actin–myosin interactions (Kobayashi and Solaro 2005). The functional importance of the cTn complex is underlined by the numerous charge mutations in these proteins that lead to familial hypertrophic cardiomyopathies (Morimoto 2008). Charged residues or phosphorylations control the intermolecular interactions between these sarcomeric proteins and regulate cardiac contractile function.
The focus of much of the literature has been on cardiac TnI, which is phosphorylated by several serine/threonine kinases (PKA, PKC, PKD, ROCK), leading to important changes in contractile function (Haworth et al. 2004; Layland et al. 2005; Vahebi et al. 2005). While TnT is not phosphorylated by PKA, its phosphorylation by PKC (at Thr197, Ser201, Thr206, and Thr287 sites in the functionally important C-terminal half of the protein that interacts with TnI, TnC, and possibly Tm) has been linked to impaired myofilament function (Sumandea et al. 2003). TnT phosphorylation by ASK1 (a stress-activated kinase that has been implicated specifically in TNF and oxidant stress responses) also has been associated with a decrease in cardiomyocyte contractility (He et al. 2003). The functional importance of TnT phosphorylation has been exposed in transgenic models where replacement of cardiac TnT with skeletal TnT (that lacks regulatory phosphorylation sites) blunts PKC-dependent depression of cardiac contraction (Montgomery et al. 2001). Mutagenesis studies (with PKC phosphorylation sites substituted by either alanine or phosphomimetic glutamate residues) implicate Thr206 as a functionally important phosphorylation site (Sumandea et al. 2003).
In the course of recent studies that examined the role of PKCδ as a TnI kinase (Sumandea et al. 2008), we identified a TnT kinase activity that could not be attributed to PKC in cardiomyocytes lysates. Studies reported herein identify Raf as a novel cardiomyocyte TnT kinase.
Materials and methods
Recombinant PKCδ was from Calbiochem. Recombinant MEK, PKA, PKCα, PKCβII, PKCε and PKD1 were from Upstate. Recombinant truncated/activated Raf-1 (amino acids 306–648 in the catalytic domain, with Y340D/Y341D substitutions) and full-length Pak-1 were obtained from Invitrogen. Other chemicals were reagent grade.
Cardiomyocytes were isolated from hearts of 2-day-old Wistar rats by a trypsin dispersion procedure that uses a differential attachment procedure followed by irradiation to enrich for cardiomyocytes. Cells were plated on protamine sulfate-coated culture dishes at a density of 5 × 106 cells/100 mm dish and grown in MEM (Gibco, BRL) supplemented with 10% fetal calf serum for 4 days. Cells were lysed in homogenization buffer (20 mM Tris–Cl, pH 7.5, 2 mM EDTA, 2 mM EGTA, 0.5 mM DTT, 0.2% Triton X-100, 50 μg/ml aprotinin, 50 μg/ml leupeptin, 50 μg/ml benzamidine, 1 mM PMSF, 5 μM pepstatin A, 1 mM sodium orthovanadate, 100 mM sodium fluoride, 10 mM sodium pyrophosphate, 0.1 μM calyculin). Cell extracts were used for in vitro kinase assays.
Troponin expression and purification
Recombinant heterotrimeric troponin complexes were prepared according to very stringent conditions designed to avoid the presence of any contaminants, as previously described (Sumandea et al. 2003). Briefly, each subunit (cardiac TnT-WT and -T206E, TnI and TnC) was expressed independently in E. coli, denatured in a 6 M urea solution and purified to >90% using a combination of ammonium sulfate fractionation, anionic and cationic exchange chromatography (on an AKTA-FPLC system), and extensive dialysis. Recombinant heterotrimeric cTn complexes were reconstituted by mixing equimolar amounts of cTnT (either wt or T206E), cTnI and cTnC in a solubilization buffer containing 6 M Urea, 50 mM Tris pH 8.0, 1 M NaCl, 5 mM MgCl2, 1 mM CaCl2, 1 mM DTT. The solution was subjected to sequential dialysis using 0.7 M NaCl, 0.4 M NaCl, and finally 0.05 M NaCl in the above buffer minus urea. cTn complex was then further purified from any contaminants on a high performance Resource Q column (GE Healthcare). Troponin complex elutes as a sharp peak well separated from any unincorporated monomeric TnI or TnC subunits. Troponin complexes were tested using in vitro reconstituted myofilament assays for their ability to regulate myosin ATPase activity in a [Ca2+] dependent manner.
In vitro kinase assays with cell extracts
In vitro kinase assays were performed with 11 μg of cardiomyocyte extract. Assays were performed in 110 μl of a reaction buffer containing 20 mM Tris–Cl, pH 7.5, 3 mM MgCl2, 0.7 mM EDTA, 0.7 mM EGTA, 0.24 mM DTT, 0.9 mM sodium vanadate, 120 mM NaCl, 0.073% Triton X-100, 0.36 mM phenylmethylsulfonyl fluoride, 0.36 mM sodium orthovanadate, 36 mM sodium fluoride, 3.6 mM sodium pyrophosphate, 0.06 μM calyculin, 15 μg of recombinant cardiac troponin complex (cTn), and [γ-32P]ATP (2 μCi, 66 μM). Incubations were for 16 min at 30°C.
In vitro kinase assays with recombinant PKCs, PKD1 and PKA
In vitro kinase assays were performed in 110 μl of a reaction buffer containing 38 mM Tris–Cl, pH 7.5, 6 mM MgCl2, 0.6 mM EDTA, 0.6 mM EGTA, 1.6 mM DTT, 136 mM NaCl, 4.2% glycerol, 83 μg/ml phosphatidylserine, 160 nM PMA, 4 μg of cTn, and [γ-32P]ATP (2 μCi, 66 μM). Incubations were for 16 min at 30°C in the presence of PKCδ (0.032 units), PKCα (0.063 units), PKCβII (0.063 units), PKCε (0.184 units), PKD1 (0.026 units), or PKA (3.84 units).
In vitro kinase assays with recombinant c-Raf-1 and Pak
In vitro kinase assays were performed in 40 μl of a reaction buffer containing 30 mM HEPES, pH 7.4, 10 mM MgCl2, 5 mM EGTA, 1 mM DTT, 115 mM NaCl, 1 mM sodium orthovanadate, 25 mM β-glycerophosphate, 7.5 μg of cTn, and [γ-32P]ATP (15 μCi, 15 μM). Incubations were for 30 min at 25°C in the absence or presence of c-Raf-1 (15 ng) or Pak (20 ng).
Troponin T phosphorylation sites have been mapped to Thr197, Ser201, Thr206, and Thr287. To determine whether Raf phosphorylate cTnT at Thr206 (the functionally critical phosphorylation site) we used recombinant troponin complexes containing equimolar amounts of cTnI, cTnC, and cTnT (either WT or harboring T206E substitution). Figure 3c shows that cTnT-T206E is not a substrate for Raf, including in assays that contain Pak to increase Raf activity. These results indicate that Raf acts as a selective cTnT-Thr206 kinase. Interestingly, Pak-dependent cTnI phosphorylation is decreased in assays with cTnT-T206E as substrate. While this finding was surprising, nonphosphorylatable TnT or TnI mutants that exert long-range effect to decrease the phosphorylation of the other subunit have been described in previous studies (Montgomery et al. 2001, 2002). Finally, Fig. 3d shows that PKCδ (a different serine/threonine kinase) phosphorylates WT- and T206E-substituted cTnT in a similar manner; PKCδ also phosphorylates cTnI. These results validate the integrity of the cTnI-T206E protein and indicate that PKCδ phosphorylates cTnT at sites other than Thr206.
Raf proteins have recently emerged as key mediators of cellular growth, differentiation, and survival mechanisms, in the heart and other tissues. The focus of most studies has been on the role of Raf-1 to activate the ERK-MAPK pathway. Using molecular approaches involving overexpressing dominant-negative forms of Raf, Raf-1 has been implicated in endothelin-1- or phenylephrine-dependent cardiomyocyte growth, sarcomeric reorganization, and atrial natriuretic factor gene expression in cardiomyocytes cultures (Harris et al. 2004) and Raf proteins have been implicated in ERK activation, ventricular hypertrophy, and survival in mice subjected to aortic banding. Studies in genetically modified mice suggest anti-apoptotic mechanisms for Raf-1 in the heart. Cardiac-specific disruption of the Raf-1 gene leads to increased cardiomyocytes apoptosis, left ventricular dilatation, and decreased systolic function at 10 weeks of age that is associated with an increase in ASK1, JNK, and p38 MAPK activities (without a detectable defect in agonist-dependent ERK activation; Harris et al. 2004). Additional studies implicate ASK1 as a particularly important Raf-1 effector that contributes to in vivo cardiac remodeling, showing that the effect of Raf-1 knockout to induce apoptosis and cardiac dilatation and to decrease cardiac contractile function is prevented in the Raf1-ASK1 double knockout (Yamaguchi et al. 2004).
Studies reported herein identify an additional role for Raf, as a cTnT-Thr206 kinase. Since cTnT-Thr206 phosphorylation has been implicated as a mechanism that attenuates force, actomyosin Mg-ATPase rate, Ca2+ sensitivity, and tension cost of mouse cardiac fiber bundles (Sumandea et al. 2003), dynamic increases in cTnT-Thr206 phosphorylation may be beneficial in instances of high-energy demand and protect the heart from over-stimulation. Finally, it is interesting to note that the Pak-Raf-Ask1 pathway may be uniquely poised to regulate contractility since Pak phosphorylates cTnI, Raf phosphorylates cTnT-Thr206 and ASK1 phosphorylates cTnT (at T197ERKS201, in the vicinity of the KRQT206EREK sequence). Future studies that examine whether Raf-1- and ASK1-dependent cTnT phosphorylations are independently regulated or whether these phosphorylation reactions are controlled in an interdependent fashion will be important, as this would function to add further complexity to the process.
This work was supported by United States Public Health Service—National Heart, Lung and Blood Institute grants HL-77860, HL-74161, and AHA-SDG 0335199 N.